Evidence map›Paper›PMID 24390333›Full record

ArticleJournal of virology2014

A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.

Brian D Quinlan, Vinita R Joshi, Matthew R Gardner, Kourosh H Ebrahimi, Michael Farzan

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. In vivo evolution of env in SHIV-AD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Characterization ofFrontiers in pharmacology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.Expert opinion on therapeutic targets · 2015
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Brian D QuinlanDepartment of Infectious Diseases, The Scripps Research Institute, Jupiter, Florida, USA.
Vinita R Joshi
Matthew R Gardner
Kourosh H Ebrahimi
Michael Farzan
Scripps Research Institute · US

Funding

Viral escape from AAV expressed transgenesP01AI100263 · NIAID · SCRIPPS FLORIDA · PI GAO, GUANGPING · 2012 to 2016
$11.9M
Therapeutic use of an enhanced form of CD4-IgR01AI091476 · NIAID · SCRIPPS FLORIDA · PI FARZAN, MICHAEL R. · 2011 to 2015
$4.3M
A double-mimetic inhibitor of HIV-1 entryR01AI080324 · NIAID · SCRIPPS FLORIDA · PI FARZAN, MICHAEL R. · 2009 to 2013
$2.3M
NIAID NIH HHS P01 AI100263NIAID NIH HHS R01 AI080324NIAID NIH HHS R01 AI091476NIAID NIH HHS R01 AI0914767
6 · The paper itself

Abstract

unlabelledThe HIV-1 envelope glycoprotein binds cooperatively to its cellular receptor CD4 and a coreceptor, principally CXCR4 or CCR5. We have previously improved a natural amino-acid form of a scorpion toxin-derived CD4-mimetic peptide and in parallel generated sulfopeptide mimetics of the CCR5 amino terminus. Here we show that some fusions of these CCR5- and CD4-mimetic peptides, expressed as immunoadhesins, neutralize HIV-1 more efficiently than CD4-Fc or equimolar mixtures of immunoadhesin forms of each peptide. Specifically, double-mimetic peptides with linkers of 11 amino acids or greater, and with the CCR5-mimetic component preceding the CD4-mimetic component, were more efficient than constructs with shorter linkers or in a reverse orientation. The potency of these constructs derives from (i) their ability to simultaneously and cooperatively bind the CD4- and CCR5-binding sites of a single gp120 monomer of the HIV-1 envelope glycoprotein trimer and (ii) the ability of the CCR5-mimetic component to prevent the CD4-mimetic peptide from promoting infection when cellular CD4 is limiting. Thus, there is a significant advantage to simultaneously targeting both conserved regions of the HIV-1 envelope glycoprotein. IMPORTANCE: This report describes a novel class of peptides that potently inhibit HIV-1 entry. These peptides simultaneously target the receptor- and coreceptor-binding sites of the HIV-1 envelope glycoprotein gp120. Peptides of this class overcome key limitations of inhibitors that target only one gp120 binding region and illustrate the utility of binding the sulfotyrosine-binding pockets of gp120.

Indexed as

Amino Acid SequenceBinding SitesCD4 AntigensCell LineHIV-1HIV Envelope Protein gp120HIV InfectionsHumansPeptidesProtein BindingReceptors, CCR5Receptors, CXCR4Receptors, HIVCD4 AntigensHIV Envelope Protein gp120PeptidesReceptors, CCR5Receptors, CXCR4Receptors, HIV

Identifiers

PMID24390333
PMCPMC3957931
OpenAlexW1966804706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.